2seventy bio (TSVT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	60.35 mm	60.35 mm	60.35 mm	60.35 mm	60.35 mm	60.35 mm
Cash burn (monthly)	17.32 mm	2.65 mm	4.65 mm	12.80 mm	3.50 mm	11.59 mm
Cash used (since last report)	88.75 mm	13.58 mm	23.82 mm	65.61 mm	17.95 mm	59.42 mm
Cash remaining	-28.41 mm	46.77 mm	36.53 mm	-5.27 mm	42.40 mm	927.12 k
Runway (months of cash)	-1.6	17.7	7.9	-0.4	12.1	0.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

TSVT institutional ownership history Ownership history

89.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	114	114	–
Opened positions	20	15	+33.3%
Closed positions	20	12	+66.7%
Increased positions	34	25	+36.0%
Reduced positions	26	37	-29.7%

13F shares	Current	Prev Q	Change
Total value	134.33 bn	211.85 bn	-36.6%
Total shares	45.95 mm	45.02 mm	+2.1%
Total puts	2.90 k	19.80 k	-85.4%
Total calls	17.30 k	121.80 k	-85.8%
Total put/call ratio	0.2	0.2	+3.1%

Largest owners	Shares	Value	Change
Kynam Capital Management	5.95 mm	$17.50 bn	0.0%
GS The Goldman Sachs Group, Inc.	4.29 mm	$12.63 bn	+1.8%
BlackRock	4.22 mm	$12.41 bn	+9.1%
Vanguard	3.76 mm	$11.06 bn	-0.3%
MS Morgan Stanley	2.92 mm	$8.58 bn	+0.9%
Newtyn Management	2.53 mm	$7.45 bn	-0.2%
BAC Bank of America	2.52 mm	$7.40 bn	+317.1%
Baker Bros. Advisors	2.50 mm	$7.34 bn	0.0%
Casdin Capital	2.00 mm	$5.88 bn	0.0%
REGN Regeneron Pharmaceuticals	1.25 mm	$3.69 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Madison Avenue Partners	579.90 k	-1.98 mm	-77.4%
BAC Bank of America	2.52 mm	+1.91 mm	+317.1%
REGN Regeneron Pharmaceuticals	1.25 mm	+1.25 mm	NEW
Deutsche Bank AG - Registered Shares	372.31 k	-958.64 k	-72.0%
TD The Toronto-Dominion Bank	800.00 k	+800.00 k	NEW
Cowen And	0.00	-800.00 k	EXIT
Engine Capital Management	703.97 k	-585.98 k	-45.4%
Western Standard	788.35 k	+502.42 k	+175.7%
BlackRock	4.22 mm	+352.56 k	+9.1%
Point72 Asset Management	310.64 k	+310.64 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TSVT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Jan 25	Victoria Eatwell	Common Stock	Grant	Acquire A	No	No	0	108,000	0.00	446,979
6 Jan 25	Victoria Eatwell	Stock Option Common Stock	Grant	Acquire A	No	No	2.64	72,000	190.08 k	72,000
6 Jan 25	Jessica Snow	Common Stock	Grant	Acquire A	No	No	0	106,150	0.00	253,329
6 Jan 25	Jessica Snow	Stock Option Common Stock	Grant	Acquire A	No	No	2.64	70,750	186.78 k	70,750
6 Jan 25	William D Baird III	Common Stock	Grant	Acquire A	No	No	0	264,000	0.00	1,126,126
6 Jan 25	William D Baird III	Stock Option Common Stock	Grant	Acquire A	No	No	2.64	176,000	464.64 k	176,000
6 Jan 25	Victoria Eatwell	Common Stock	Sell	Dispose S	No	No	2.7785	97	269.51	338,979
6 Jan 25	William D Baird III	Common Stock	Sell	Dispose S	No	No	2.7785	763	2.12 k	862,126
3 Jan 25	Victoria Eatwell	Common Stock	Sell	Dispose S	No	No	2.9359	1,013	2.97 k	339,076
3 Jan 25	William D Baird III	Common Stock	Sell	Dispose S	No	No	2.9359	31,718	93.12 k	862,889

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data

7 Feb 25

Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.

Press releases

From Benzinga Pro

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

25 Feb 25

2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

6 Feb 25

$242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024 Net cash burn of $9 million in the fourth quarter of 2024; path to